The resolvin D2 – GPR18 axis is expressed in human coronary atherosclerosis and transduces atheroprotection in apolipoprotein E deficient mice - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Biochemical Pharmacology Année : 2022

The resolvin D2 – GPR18 axis is expressed in human coronary atherosclerosis and transduces atheroprotection in apolipoprotein E deficient mice

Résumé

Chronic inflammation in atherosclerosis reflects a failure in the resolution of inflammation. Pro-resolving lipid mediators derived from omega-3 fatty acids reduce the development of atherosclerosis in murine models. The aim of the present study was to decipher the role of the specialized proresolving mediator (SPM) resolvin D2 (RvD2) in atherosclerosis and its signaling through the G-protein coupled receptor (GPR) 18. The ligand and receptor were detected in human coronary arteries in relation to the presence of atherosclerotic lesions and its cellular components. Importantly, RvD2 levels were significantly higher in atherosclerotic compared with healthy human coronary arteries. Furthermore, apolipoprotein E (ApoE) deficient hyperlipidemic mice were treated with either RvD2 or vehicle in the absence and presence of the GPR18 antagonist O-1918. RvD2 significantly reduced atherosclerosis, necrotic core area, and pro-inflammatory macrophage marker expression. RvD2 in addition enhanced macrophage phagocytosis. The beneficial effects of RvD2 were not observed in the presence of O-1918. Taken together, these results provide evidence of atheroprotective pro-resolving signalling through the RvD2-GPR18 axis.
Fichier principal
Vignette du fichier
1-s2.0-S0006295222001691-main.pdf (6.59 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04020850 , version 1 (09-03-2023)

Identifiants

Citer

Matthieu Bardin, Sven-Christian Pawelzik, Jeremy Lagrange, Ali Mahdi, Hildur Arnardottir, et al.. The resolvin D2 – GPR18 axis is expressed in human coronary atherosclerosis and transduces atheroprotection in apolipoprotein E deficient mice. Biochemical Pharmacology, 2022, 201 (11), pp.115075. ⟨10.1016/j.bcp.2022.115075⟩. ⟨hal-04020850⟩
14 Consultations
17 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More